{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,11]],"date-time":"2025-12-11T13:17:12Z","timestamp":1765459032483,"version":"3.46.0"},"reference-count":35,"publisher":"MDPI AG","issue":"24","license":[{"start":{"date-parts":[[2025,12,11]],"date-time":"2025-12-11T00:00:00Z","timestamp":1765411200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JCM"],"abstract":"<jats:p>Background\/Objectives: Ceftriaxone is widely used as empirical antimicrobial therapy (EAT) for urinary tract infections (UTIs). However, healthcare-associated urinary tract infections (HCA-UTIs) are often associated with inadequate EAT (IEAT). This study aims to evaluate the clinical impact of ceftriaxone as EAT in patients admitted to the hospital with community-onset HCA-UTIs in a setting with relatively high rates of antimicrobial resistance. Methods: A prospective observational study was conducted, comparing patients who received empirical treatment with ceftriaxone to those treated with other antibiotics. Results: A total of 235 cases were analyzed, 50.2% received ceftriaxone as EAT. The median age was 79 years, and 47.2% of patients were female. IEAT was significantly more frequent in the ceftriaxone group (36.4% vs. 17.1%, p = 0.001). Thirty-day mortality was 11.1%, with no significant difference between the ceftriaxone and non-ceftriaxone groups (11.9% vs. 10.3%, p = 0.752) but the use of antibiotics other than ceftriaxone was associated with a longer hospital stay (6 [4\u20138] vs. 5 [3\u20137] days, p = 0.037). The use of ceftriaxone as EAT was not associated with an increased risk of recurrence (16.1% vs. 15.4%, p = 0.709). Conclusions: In summary, empirical ceftriaxone use in patients with community-onset HCA-UTI was associated with a higher rate of inappropriate empirical therapy; however, it did not increase mortality or recurrence and was associated with a shorter hospital stay. These findings support the use of ceftriaxone as a potential option in selected patients without septic shock, while highlighting the importance of considering local resistance patterns and individual patient risk factors.<\/jats:p>","DOI":"10.3390\/jcm14248761","type":"journal-article","created":{"date-parts":[[2025,12,11]],"date-time":"2025-12-11T12:57:41Z","timestamp":1765457861000},"page":"8761","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Clinical Impact of Empiric Ceftriaxone for Hospitalized Patients with Community-Onset Healthcare-Associated UTIs"],"prefix":"10.3390","volume":"14","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8779-3001","authenticated-orcid":false,"given":"Manuel","family":"Madrazo","sequence":"first","affiliation":[{"name":"Doctor Peset University Hospital, Universitat de Val\u00e8ncia, Avda Gaspar Aguilar n 90, 46017 Valencia, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7252-8961","authenticated-orcid":false,"given":"Ian","family":"L\u00f3pez-Cruz","sequence":"additional","affiliation":[{"name":"Doctor Peset University Hospital, Universitat de Val\u00e8ncia, Avda Gaspar Aguilar n 90, 46017 Valencia, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3214-7843","authenticated-orcid":false,"given":"Laura","family":"Piles","sequence":"additional","affiliation":[{"name":"Doctor Peset University Hospital, Universitat de Val\u00e8ncia, Avda Gaspar Aguilar n 90, 46017 Valencia, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mar\u00eda","family":"Civera","sequence":"additional","affiliation":[{"name":"Doctor Peset University Hospital, Universitat de Val\u00e8ncia, Avda Gaspar Aguilar n 90, 46017 Valencia, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5357-6340","authenticated-orcid":false,"given":"Jos\u00e9 Mar\u00eda","family":"Eiros","sequence":"additional","affiliation":[{"name":"Rio Hortega University Hospital, Universidad de Valladolid, 47014 Valladolid, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7915-375X","authenticated-orcid":false,"given":"Juan","family":"Alberola","sequence":"additional","affiliation":[{"name":"Doctor Peset University Hospital, Universitat de Val\u00e8ncia, Avda Gaspar Aguilar n 90, 46017 Valencia, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7479-3408","authenticated-orcid":false,"given":"Arturo","family":"Artero","sequence":"additional","affiliation":[{"name":"Doctor Peset University Hospital, Universitat de Val\u00e8ncia, Avda Gaspar Aguilar n 90, 46017 Valencia, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2025,12,11]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"469580231168746","DOI":"10.1177\/00469580231168746","article-title":"Incidence of Urinary Tract Infection Among Patients: Systematic Review and Meta-Analysis","volume":"60","author":"Mengistu","year":"2023","journal-title":"Inquiry"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"1756287219832172","DOI":"10.1177\/1756287219832172","article-title":"An introduction to the epidemiology and burden of urinary tract infections","volume":"11","author":"Medina","year":"2019","journal-title":"Ther. Adv. Urol."},{"key":"ref_3","doi-asserted-by":"crossref","unstructured":"Carcamo, P., Walter, E., Frei, C.R., Yang, L., Cadena, J., and Hopkins, T. (2025). A comparison of empiric therapy with cefazolin versus ceftriaxone for patients with complicated urinary tract infections in a tertiary care veterans affairs medical center. BMC Infect. Dis., 25.","DOI":"10.1186\/s12879-025-10494-5"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1016\/j.jhin.2024.05.020","article-title":"Risk factors and clinical impact of multidrug resistance in healthcare-associated bacteraemic urinary tract infections: A post-hoc analysis of a multicentre prospective cohort in Spain","volume":"151","author":"Sendra","year":"2024","journal-title":"J. Hosp. Infect."},{"key":"ref_5","doi-asserted-by":"crossref","unstructured":"Zilberberg, M.D., Nathanson, B.H., Sulham, K., and Shorr, A.F. (2021). Multiple antimicrobial resistance and outcomes among hospitalized patients with complicated urinary tract infections in the US, 2013\u20132018: A retrospective cohort study. BMC Infect. Dis., 21.","DOI":"10.1186\/s12879-021-05842-0"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1111\/ggi.13856","article-title":"Predictive factors for Enterococcus faecalis in complicated community-acquired urinary tract infections in older patients","volume":"20","author":"Madrazo","year":"2020","journal-title":"Geriatr. Gerontol. Int."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"4684","DOI":"10.1128\/AAC.00469-10","article-title":"Prevalence of antimicrobial-resistant pathogens in Canadian hospitals: Results of the Canadian Ward Surveillance Study (CANWARD 2008)","volume":"54","author":"Zhanel","year":"2010","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"962","DOI":"10.1111\/1469-0691.12089","article-title":"Healthcare-associated, community-acquired and hospital-acquired bacteraemic urinary tract infections in hospitalized patients: A prospective multicentre cohort study in the era of antimicrobial resistance","volume":"19","author":"Horcajada","year":"2013","journal-title":"Clin. Microbiol. Infect."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"791","DOI":"10.7326\/0003-4819-137-10-200211190-00007","article-title":"Health care-associated bloodstream infections in adults: A reason to change the accepted definition of community-acquired infections","volume":"137","author":"Friedman","year":"2002","journal-title":"Ann. Intern. Med."},{"key":"ref_10","unstructured":"Madrazo, M. (2020). Aplicaci\u00f3n de Los Criterios de Sepsis-3 En La Infecci\u00f3n Urinaria. [Ph.D. Thesis, University of Val\u00e8ncia]."},{"key":"ref_11","doi-asserted-by":"crossref","unstructured":"Shimoni, Z., Salama, H., Finn, T., and Froom, P. (2024). Is It Safe to Treat Stable Patients with Bacteremic Urinary Tract Infections with High-Resistant-Rate Antibiotics?. Diagnostics, 14.","DOI":"10.3390\/diagnostics14151620"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"762","DOI":"10.1001\/jama.2016.0288","article-title":"Assessment of Clinical Criteria for Sepsis: For the Third International Consensus Definitions for Sepsis and Septic Shock (Sepsis-3)","volume":"315","author":"Seymour","year":"2016","journal-title":"JAMA"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"1245","DOI":"10.1016\/0895-4356(94)90129-5","article-title":"Validation of a combined comorbidity index","volume":"47","author":"Charlson","year":"1994","journal-title":"J. Clin. Epidemiol."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"818","DOI":"10.1097\/00003246-198510000-00009","article-title":"APACHE II. A severity of disease classification system","volume":"13","author":"Knaus","year":"1985","journal-title":"Crit. Care Med."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1016\/j.amjms.2016.05.031","article-title":"Effect of Bacteremia in Elderly Patients with Urinary Tract Infection","volume":"352","author":"Artero","year":"2016","journal-title":"Am. J. Med. Sci."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1111\/j.1469-0691.2011.03570.x","article-title":"Multidrug-resistant, extensively drut-resistant and pandrug-resistant bacteria: An international expert proposal for interim standard definitions for acquired resistance","volume":"18","author":"Magiorakos","year":"2012","journal-title":"Clin. Microbiol. Infect."},{"key":"ref_17","unstructured":"(2025). 2025 Guideline on Management and Treatment of Complicated Urinary Tract Infections: Selection of Antibiotic Therapy for Complicated UTI, Infectious Diseases Society of America."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1016\/j.annemergmed.2021.01.003","article-title":"Third-Generation Cephalosporin Resistance and Associated Discordant Antibiotic Treatment in Emergency Department Febrile Urinary Tract Infections","volume":"78","author":"Mark","year":"2021","journal-title":"Ann. Emerg. Med."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1016\/S1473-3099(20)30477-1","article-title":"Inappropriate empirical antibiotic therapy for bloodstream infections based on discordant in-vitro susceptibilities: A retrospective cohort analysis of prevalence, predictors, and mortality risk in US hospitals","volume":"21","author":"Kadri","year":"2021","journal-title":"Lancet Infect. Dis."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1016\/j.diagmicrobio.2017.07.011","article-title":"Long-term outcomes of inappropriate antibiotic therapy for upper urinary tract infections caused by extended-spectrum beta-lactamase-producing Enterobacteriaceae: A retrospective cohort study","volume":"89","author":"Greenhouse","year":"2017","journal-title":"Diagn. Microbiol. Infect. Dis."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1093\/cid\/ciy418","article-title":"Risk Factors for Treatment Failure and Mortality Among Hospitalized Patients with Complicated Urinary Tract Infection: A Multicenter Retrospective Cohort Study (RESCUING Study Group)","volume":"68","author":"Babitch","year":"2019","journal-title":"Clin. Infect. Dis."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1007\/s10096-021-04392-2","article-title":"Increasing rates of extended-spectrum B-lactamase-producing Escherichia coli and Klebsiella pneumoniae in uncomplicated and complicated acute pyelonephritis and evaluation of empirical treatments based on culture results","volume":"41","author":"Kayaaslan","year":"2022","journal-title":"Eur. J. Clin. Microbiol. Infect. Dis."},{"key":"ref_23","doi-asserted-by":"crossref","unstructured":"Nocua-B\u00e1ez, L.C., Reyes, P., and Cortes, J.A. (2025). Effect of inadequate treatment in adult patients with community-acquired acute pyelonephritis due to Enterobacterales under empirical management with cefazolin. Antibiotics, 14.","DOI":"10.3390\/antibiotics14020197"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"e01317-17","DOI":"10.1128\/AAC.01317-17","article-title":"A Cohort Study of Risk Factors That Influence Empirical Treatment of Patients with Acute Pyelonephritis","volume":"61","author":"Andreu","year":"2017","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1016\/S1473-3099(23)00686-2","article-title":"Efficacy and safety of a structured de-escalation from antipseudomonal beta-lactams in bloodstream infections due to Enterobacterales (SIMPLIFY): An open-label, multicentre, randomised trial","volume":"24","year":"2024","journal-title":"Lancet Infect. Dis."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1016\/j.ijantimicag.2017.03.024","article-title":"Clinical benefits of antimicrobial de-escalation in adults with community-onset monomicrobial Escherichia coli, Klebsiella species and Proteus mirabilis bacteremia","volume":"50","author":"Lee","year":"2017","journal-title":"Int. J. Antimicrob. Agents"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1016\/j.jinf.2019.06.014","article-title":"Prognosis of urinary tract infection caused by KPC-producing Klebsiella pneumoniae: The impact of inappropriate empirical treatment","volume":"79","author":"Machuca","year":"2019","journal-title":"J. Infect."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1016\/j.jgar.2021.05.016","article-title":"Impact of inappropriate empirical antibiotic treatment on clinical outcomes of urinary tract infections caused by Escherichia coli: A retrospective cohort study","volume":"26","author":"Zhu","year":"2021","journal-title":"J. Glob. Antimicrob. Resist."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"ofac034","DOI":"10.1093\/ofid\/ofac034","article-title":"Efficacy of Noncarbapenem \u03b2-Lactams Compared to Carbapenems for Extended-Spectrum \u03b2-Lactamase\u2013Producing Enterobacterales Urinary Tract Infections","volume":"9","author":"Anderson","year":"2022","journal-title":"Open Forum Infect. Dis."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"e00862-20","DOI":"10.1128\/AAC.00862-20","article-title":"Escherichia coli Resistance to Fluoroquinolones in Community-Acquired Uncomplicated Urinary Tract Infection in Women: A Systematic Review","volume":"64","author":"Stapleton","year":"2020","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"100736","DOI":"10.1016\/j.lanepe.2023.100736","article-title":"Pseudomonas aeruginosa antibiotic susceptibility profiles, genomic epidemiology and resistance mechanisms: A nation-wide five-year time lapse analysis","volume":"34","author":"Taltavull","year":"2023","journal-title":"Lancet Reg. Health Eur."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1007\/s00210-023-02622-2","article-title":"Re-evaluating the suitability of using fluoroquinolones in the treatment of infections in the context of FQ consumption and correlating changes to microorganism resistance levels in EU\/EEA countries between 2016 and 2021","volume":"397","author":"Serwacki","year":"2024","journal-title":"Naunyn-Schmiedeberg\u2019s Arch. Pharmacol."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1089\/mdr.2011.0203","article-title":"Diversity of clones and genotypes among vancomycin-resistant clinical Enterococcus isolates recovered in a Spanish hospital","volume":"18","author":"Lopez","year":"2012","journal-title":"Microb. Drug Resist."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1089\/mdr.2021.0171","article-title":"Establishment and Persistence of Glycopeptide-Resistant Enterococcus faecium ST80 and ST117 Clones Within a Health Care Facility Located in a Low-Prevalence Geographical Region","volume":"28","author":"Fernandez","year":"2022","journal-title":"Microb. Drug Resist."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"478","DOI":"10.1016\/j.ijantimicag.2019.06.015","article-title":"Comparison of antibiotic treatment guidelines for urinary tract infections in 15 European countries: Results of an online survey","volume":"54","author":"Malmros","year":"2019","journal-title":"Int. J. Antimicrob. Agents"}],"container-title":["Journal of Clinical Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2077-0383\/14\/24\/8761\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,11]],"date-time":"2025-12-11T13:10:18Z","timestamp":1765458618000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2077-0383\/14\/24\/8761"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,11]]},"references-count":35,"journal-issue":{"issue":"24","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["jcm14248761"],"URL":"https:\/\/doi.org\/10.3390\/jcm14248761","relation":{},"ISSN":["2077-0383"],"issn-type":[{"type":"electronic","value":"2077-0383"}],"subject":[],"published":{"date-parts":[[2025,12,11]]}}}